Alosetron, n 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

L. A. Houghton, J. M. Foster, P. J. Whorwell

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Background: Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P = 0.128), which was confirmed in controls (r = 0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.

Original languageEnglish (US)
Pages (from-to)775-782
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume14
Issue number6
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Irritable Bowel Syndrome
Healthy Volunteers
Placebos
Cross-Over Studies
Meals
alosetron
Hydrogen
X-Rays
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Alosetron, n 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. / Houghton, L. A.; Foster, J. M.; Whorwell, P. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 14, No. 6, 2000, p. 775-782.

Research output: Contribution to journalArticle

@article{bbaa3d6a79dc403991e8c7d106587879,
title = "Alosetron, n 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers",
abstract = "Background: Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P = 0.128), which was confirmed in controls (r = 0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.",
author = "Houghton, {L. A.} and Foster, {J. M.} and Whorwell, {P. J.}",
year = "2000",
doi = "10.1046/j.1365-2036.2000.00762.x",
language = "English (US)",
volume = "14",
pages = "775--782",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Alosetron, n 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

AU - Houghton, L. A.

AU - Foster, J. M.

AU - Whorwell, P. J.

PY - 2000

Y1 - 2000

N2 - Background: Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P = 0.128), which was confirmed in controls (r = 0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.

AB - Background: Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P = 0.128), which was confirmed in controls (r = 0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0033625752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033625752&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2000.00762.x

DO - 10.1046/j.1365-2036.2000.00762.x

M3 - Article

VL - 14

SP - 775

EP - 782

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -